| Serial Number | 98855334 |
| Word Mark | TELOID |
| Filing Date | Friday, November 15, 2024 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Monday, June 2, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 24, 2025 |
| Goods and Services | Research and development of vaccines and medicine; medicine research; medical and pharmacological research services; scientific research services for medical purposes in the field of oncology; development of pharmaceutical preparations and medicines; consultancy in analysis of biology sequence processing for medical research purposes; laboratory research in the field of pharmaceuticals; pharmaceutical drug development services; medical research laboratory services; scientific investigations for medical purposes; quality management services, namely, quality analysis and evaluation in the field of medical product development; drug discovery services; research on the subject of pharmaceuticals; medical research laboratory services; development of biological pharmaceutical preparations; research and development of amino acid for medical purpose; development of cell therapy products; laboratory research services relating to pharmaceuticals; scientific research for medical purposes in the field of cancerous diseases; conducting clinical studies of medicines for others; scientific research in the field of pharmacy; pharmaceutical research and development; biotechnology research; biomedical research services; pharmaceutical drug development; stem cell research services; pharmaceutical research services; consultancy in analysis of genomics for medical research purposes; basic and clinical research in the field of respiratory science and medicine; conducting early evaluations in the field of new pharmaceuticals; pharmaceutical products evaluation; scientific research for medical purposes in the area of cancerous diseases; research and development of peptide for medical purposes |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, December 10, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | GemVax & KAEL CO., LTD. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Daejeon 34036 KR |
| Event Date | Event Description |
| Friday, November 15, 2024 | NEW APPLICATION ENTERED |
| Friday, November 15, 2024 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, December 10, 2024 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Saturday, April 26, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, May 12, 2025 | ASSIGNED TO EXAMINER |
| Tuesday, December 10, 2024 | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED |
| Monday, May 19, 2025 | EXAMINERS AMENDMENT E-MAILED |
| Monday, May 19, 2025 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, May 19, 2025 | EXAMINER'S AMENDMENT ENTERED |
| Monday, May 19, 2025 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, May 19, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |